RankAlpha logo
Back to Rankings

LRMR

Larimar TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The constructive case is still regulatory execution: Q2 2026 topline open-label data, Phase 3 screening planned for Q2 2026, first-patient dosing expected around mid-2026, and a June 2026 BLA target together create a visible catalyst stack into mid-2026 [#8-K-2026-03-19][#10-K-2026-03-19].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +16.3.
What can break
FDA could disagree with the accelerated-approval package, require more data, or determine the safety database is inadequate at BLA review.
Momentum
16
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.20 · Bull $10.00 · Bear $2.20
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $14.40
Why
Momentum16 · Δ7d +17.8
Value41 · Δ7d -0.1
Sentiment100 · Δ7d +16.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
16
26% active weight
Current posture
7d trendImproving
Δ7d
+17.8
Δ21d
+19.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
100
34% active weight
Current posture
7d trendImproving
Δ7d
+16.3
Δ21d
-0.0
Why this grade

Composite grade B. Momentum 15.9 / Value 41.1 / Sentiment 100.0

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$384.37M
Beta
1.01
Shares Out
104.38M
P/E (TTM) · Derived
-1.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.28
Rev YoY
-
EPS YoY
-28.3%
Gross Margin
-
Op Margin
-
Net Debt
-$132.79M
Current Ratio
4.29
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology